BJH - volume 16, issue 2, april 2025
B. Heyrman MD, S. Meers MD, S. Sid MD, K. Van Eygen MD, N. De Beule MD, PhD, M. Clauwaert MD, H. Maes MD, A. Salembier MD, J. Lemmens MD, A. Van De Velde MD, PhD, D. Selleslag MD, J. Bouziotis Msc, N. Put MD, A. De Becker MD, PhD
SUMMARY
This report on the real life use of luspatercept in Belgium, describes data of 77 patients. In the response analysis, 65.8% showed a response to treatment, including 35.4% that reached transfusion independency for a minimum of eight weeks. In the responding group, the duration of treatment was at least 38 weeks in 75% of patients. Reasons to stop treatment were adverse event (16,3%), death (23,3%), no response (34,9%) and disease progression (25,6%). One patient stopped treatment due to pronounced fatigue although having an erythroid response. These data confirm the efficacy of luspatercept and the need for real-life data on quality of life.
(BELG J HEMATOL 2025;16(2):65–9)
Read more
Top
